Lumanity

Overview

Lumanity is a global life sciences strategic services partner built through Arsenal Capital Partners’ rapid roll-up of eight specialized firms between 2020-2022, launching under the unified Lumanity brand on March 14, 2022 (MM+M; Arsenal Capital). The firm’s tagline — “We Engineer Breakthrough Value” — signals its focus on evidence-based value demonstration throughout the drug commercialization lifecycle.

Lumanity organizes capabilities across four pillars. Strategy: commercialization consulting (200+ consultants, 100+ brands annually, average client partnerships of 10-15 years), market insight, clinical and regulatory strategy (>100 FDA interactions in 5 years, preferred FDA Advisory Committee vendor), and medical affairs. Evidence: HEOR (economic modeling, HTA submissions across NICE, ICER, CDA-AMC, EU JCA — including “firsts” in CAR-T and immuno-oncology HTA submissions at NICE), patient-centered outcomes (100+ COA studies, 50+ COAs developed), and real-world evidence (proprietary PHARMO Data Network in Netherlands, HealthVerity US partnership). Engagement: medical/scientific communications, market access and payer engagement (50+ payer submissions across 20+ countries annually), patient strategy, and brand communications. Technology: the EDAI (Expert-Directed AI) platform built on proprietary GAIL generative AI (Lumanity Capabilities).

Lumanity’s specialty is the breadth of the integration: no other comparably scaled firm combines HEOR, RWE, market access, regulatory strategy, medical communications, brand communications, and commercial strategy under a single P&L with unified client delivery.

Competitive Positioning

Formation — not from Envision Pharma Group: Contrary to initial assumptions, Lumanity has no connection to Envision Pharma Group (which is GHO Capital-backed, a separate company). Lumanity was built by Arsenal Capital Partners through acquisitions of: BresMed (UK HEOR, 2020), Cello Health (UK medical affairs, 2020), Guidemark Health (US med comms, 2021), Cyan Health (US payer access, 2022), Zipher Medical Affairs (2022), Innovative Edge (UK launch management, 2022), Endpoint Outcomes (US COA/PCO, 2022), and Clarion Healthcare (US strategy consulting, November 2022) (Arsenal Capital).

Differentiation vs. Trinity: Lumanity’s global EU/HTA depth (Sheffield BresMed roots, London Cello Health heritage, PHARMO data in Netherlands) exceeds Trinity’s primarily US-focused analytics. Lumanity adds evidence generation, medical communications, and regulatory strategy that Trinity does not offer in-house.

Differentiation vs. Precision AQ: Lumanity is broader (adds HEOR, med comms, regulatory, RWE) while Precision AQ has deeper US payer data infrastructure (Access Made Possible, Payer Master, 90%+ covered lives). As CEO Jon Williams’ deputy Tom Murtagh stated: “Unlike single-service consultancies or siloed holding companies, Lumanity was designed from the outset as an integrated partner” (Lumanity VIP).

Ex-US coverage: With 11 offices across the US, UK, Germany, Switzerland, Netherlands, and India, plus work in 50+ countries, Lumanity has the strongest international footprint among these four vendors (Lumanity Contact).

Recent Developments (2024-2026)

AI platform (August 2025): Launched EDAI (Expert-Directed Applied Intelligence) platform built on GAIL (Generative AI by Lumanity), a proprietary in-house generative AI system developed since 2023. Applied for ISO 42001 AI management certification — one of the first pharma services firms to pursue this (Lumanity EDAI).

Value framework (September 2025): Launched the Value Inflection Point (VIP) Framework — a methodology for identifying and capitalizing on critical commercialization decision points from discovery to delivery (Lumanity VIP).

IRA leadership (2024): Conducted first-ever comprehensive support for a Top 20 pharma through IRA Medicare Drug Price Negotiation (Cycle 1), deploying 40+ experts and securing a higher Maximum Fair Price than a competitor’s submission — a significant proof point (Lumanity IRA).

Partnerships: Sorcero AI for medical communications and Plain Language Summaries (March 2024); PHARMO Institute for EU real-world data (July 2023, deepened to integration); HealthVerity for US data access (November 2022) (Lumanity Sorcero).

Recognition: MM+M Agency 100 (2024, 2025); MM+M Pinnacle Award for CEO Jon Williams (2025); MediaPost Best Use of Data for FOTIVDA/AVEO Oncology omnichannel campaign.

Client Types

Large pharma (“nearly all” top pharma companies), 100+ biotech companies, and medical device manufacturers. Dedicated biotech advisory practice with Pennsylvania Biotechnology Center partnership. Named clients include Apellis, Shionogi, Calliditas (Tarpeyo), Stemline, Daiichi Sankyo, UCB, and AVEO Oncology/Sanofi (Lumanity About; MM+M 2023). Key therapeutic areas: oncology (dedicated Center of Excellence), immunology, neuroscience, cell and gene therapy, rare diseases (especially ultra-rare/orphan), and infectious disease/AMR. Geographic coverage spans US, UK/EU (strong), Canada, Japan, and India, with work in 50+ countries.

Technology & Data

EDAI platform: Proprietary AI framework built on GAIL (in-house generative AI). Named technology products include ONEE (omnichannel analytics, used in AVEO Oncology campaign driving double-digit Rx growth), Expert Navigator, Pathway, Ignite (launch management from Innovative Edge), and MessageAlign (regulatory submission narrative tool). Applied for ISO 42001 AI certification (Lumanity Technology).

Proprietary data: PHARMO Data Network (Netherlands, top-10 EMA-trusted source), HealthVerity partnership (largest US interoperable healthcare data ecosystem), and Sorcero MIM platform for medical insights management (Lumanity RWE).

Financial Context

Revenue: $62.3M (2021) to $106.9M (2022, +72%) per MM+M. Current estimates range from ~$130M (Management Consulted) to $231M (ZoomInfo); actual figure likely in the $130-200M+ range. MM+M figures may capture only the US healthcare marketing segment, not full global operations.

Ownership: Arsenal Capital Partners ($10B+ in institutional equity funds, New York). No exit announced as of April 2026. Arsenal’s typical 5-7 year hold (initial acquisitions from 2020) suggests a potential exit in the 2025-2027 window.

Employees: ~1,200 across 11 locations. Revenue per employee is relatively low ($85-170K range depending on estimate), suggesting either lower billing rates than US-centric peers or a significant proportion of lower-cost UK/EU/India headcount.

Analyst Observations

Lumanity is the most ambitiously assembled firm in this batch — eight acquisitions in under three years creating a genuinely integrated end-to-end platform. The strategic logic is sound: pharma buyers increasingly want integrated evidence-to-commercialization partners rather than separate HEOR, med comms, and market access vendors. The IRA Cycle 1 win (securing a higher Maximum Fair Price than a competitor) is an unusually concrete proof point. Key risks include integration complexity (eight legacy cultures), PE exit timing, and the relatively low revenue-per-employee suggesting margin pressure or significant non-US headcount. Lumanity is a strong acquisition target for a larger platform (IQVIA, Inizio, WPP Health) seeking EU evidence/HTA depth. The PHARMO Data Network is a genuinely differentiated data asset with EMA recognition that no competitor can easily replicate. Compared to Trinity (stronger US brand, benchmarking data moat) and Precision AQ (deeper US payer data infrastructure), Lumanity’s edge is global breadth, HEOR/evidence depth, and regulatory strategy capabilities.

Related concepts: Specialty Drug Commercialization, Biosimilars & Pharma Services

Sources

• Lumanity website
• Lumanity Capabilities
• MM+M — Lumanity rebrand
• Arsenal Capital — Lumanity launch
• Arsenal Capital — Clarion acquisition
• Lumanity EDAI launch
• Lumanity VIP Framework
• Lumanity IRA
• Lumanity Sorcero partnership
• Lumanity Technology
• MM+M Agency 100 2023
• Management Consulted
• Wave 3 Batch D research